|
|
Effectiveness of SGLT2 Inhibitor for Type 2 Diabetic Nephropathy and Its Correlation with SUA Smad1 Protein and Lipoprotein |
HAO Limei, SONG Wei, WANG Pei, et al |
Dingzhou People's Hospital, Hebei Baoding 073000, China |
|
|
Abstract Objective: To observe the effectiveness of SGLT2 inhibitor on type 2 diabetic nephropathy (T2DN) and analyze the correlation between T2DN and serum uric acid (SUA), Smad1 protein and lipoprotein.Methods: The clinical data of 72 patients with T2DN admitted in our hospital from April 2020 to March 2022 (study group) were analyzed retrospectively. Based on the urinary albumin excretion rate (UAER), the number of patients with early stage diabetic nephropathy (UAER 30-300mg/24h) and clinical diabetic nephropathy (UAER >300mg/24h) were counted, and the treatment effect and adverse effects were evaluated after receiving SGLT2 inhibitor treatment (10mg/dose, 1d/dose) for 3 consecutive months.Another 54 healthy individuals who underwent health checkups at our hospital during the same period were selected as the control group. The levels of SUA, Smad1 protein and lipoprotein were compared in different populations, and the correlation between the above factors and UAER was analyzed by Spearman.Results: The SUA, Smad1 protein, and lipoprotein levels in the study group were higher than those in the control group (P<0.05). 72 patients with T2DN had an overall effectiveness of 87.50% (63/72) after treatment, and the overall incidence of adverse effects was 9.72% (7/72). After treatment, SUA, Smad1 protein, and lipoprotein levels were reduced in T2DN patients compared with those before treatment (P<0.05). Statistically, there were 45 cases in the early diabetic nephropathy group and 27 cases in the clinical diabetic nephropathy group. Before treatment, SUA, Smad1 protein and lipoprotein levels in the early diabetic nephropathy group were lower than those in the clinical diabetic nephropathy group (P<0.05). After treatment, the levels of SUA, Smad1 protein and lipoprotein decreased in both groups compared with those before treatment, with the early diabetic nephropathy group being lower than the clinical diabetic nephropathy group (P<0.05). Spearman analysis showed that the expression of SUA, Smad1 protein and lipoprotein were positively correlated with UAER (P<0.001).Conclusion: SUA, Smad1 protein and lipoprotein were highly expressed in T2DN patients. SGLT2 inhibitor treatment could reduce the levels of SUA, Smad1 protein and lipoprotein, with low adverse reactions. The clinical detection of SUA, Smad1 protein and lipoprotein levels can reflect the degree of renal injury in patients, and has certain guiding value for formulating treatment plans.
|
|
|
|
|
[1] 魏齐铭,钟小燕,张成斌,赵俊轶,黄毅岚.SGLT2抑制剂治疗2型糖尿病肾脏安全性的Meta分析[J].中国新药与临床杂志,2019,38(4):233-244. [2] Wittrup H H,Tybjaerg-Hansen A,Nordestgaard B G.Lipoprotein lipase mutations,plasma lipids and lipoproteins,and risk of ischemic heart disease.A meta-analysis[J].Circulation,2019,99(22):2901-2907. [3] 赵凡,丁国华.2型糖尿病肾病患者肾血流阻力指数与血清脂蛋白a对肾功能进展的预测[J].医学研究杂志,2019,48(11):24-30. [4] 廖哲,陈威妮,陆梓华.SGLT-2抑制剂联合ACEI制剂治疗糖尿病肾病的疗效及对血清CysC、β2-MG、hs-CRP的影响[J].海南医学,2022,33(9):1115-1118. [5] 李昌艳,刘娟,顾芳,等.2型糖尿病患者进展为早期糖尿病肾脏病的影响因素分析[J].中国全科医学,2020,23(26):3291-3296. [6] 黄贵锐,孙国明.2型糖尿病肾病患者血清胆红素及血尿酸水平的变化及意义[J].医学临床研究,2019,36(6):1066-1068. [7] Jamie G,Alison L,Joseph N,et al.Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration[J].American Journal of Health-System Pharmacy,2022,20(14):126-128. [8] 李文丛,苗红,朱蕾,等.阿格列汀对早期2型糖尿病肾病患者尿蛋白的影响[J].中华全科医师杂志,2019,18(3):241-245. [9] 林海霞,耿明慧,黎煜妍,等.SGLT-2抑制剂治疗2型糖尿病伴不同程度肾损害患者安全性的Meta分析[J].武汉大学学报:医学版,2022,43(1):102-109. [10] 宁红,饶友义,谢佳峻,等.SGLT-2抑制剂与其他降糖药物对比治疗2型糖尿病有效性与安全性的网状Meta分析[J].中国医院药学杂志,2019,39(24):2529-2536. [11] 刘毅龙,陈鹏宇,雷江,等.SGLT-2抑制剂在2型糖尿病合并心血管疾病治疗中的应用研究进展[J].陕西医学杂志,2019,48(3):407-409. [12] 孔晓艳,鲁-兵.SGLT2抑制剂对2型糖尿病患者血尿酸水平的影响[J].国际内分泌代谢杂志,2020,40(2):97-99. [13] 景晓莉.高原低氧环境下2型糖尿病患者血清HIF-1α、VEGF与尿液smad1表达的相关性分析[J].中国实验诊断学,2020,24(6):945-948. |
|
|
|